Results 231 to 240 of about 92,046 (305)

Eligibility Criteria in Advanced Urothelial Cancer Clinical Trials: An Assessment of Modernization and Inclusion. [PDF]

Cancer Med
Mercier BD, Govindarajan A, Castro DV, Li X, Philip EJ, Feng MI, Prajapati SR, Chan EH, Lee KO, Sehgal I, Patel J, O'Dell A, Chehrazi-Raffle A, Ebrahimi H, Rock A, Zengin ZB, Meza LA, Dizman N, Hsu J, Liu S, Dorff TB, Pal SK, Tripathi A.   +22 more
europepmc   +1 more source

Targeting Tumor Dormancy and Recurrence: Molecular Mechanisms and Peptide Therapeutic Delivery

MedComm – Oncology, Volume 5, Issue 1, March 2026.
This review summarizes the molecular mechanisms that regulate tumor dormancy and its role in cancer recurrence, with emphasis on immune evasion, extracellular matrix remodeling, metabolic regulation and angiogenic switching. It further discusses emerging peptide–based therapeutic strategies aimed at detecting, modulating, and eliminating dormant tumor ...
Abdur Raheem Aleem, Atif Ali, Wajid Ali, Yuying Cheng, Zhibin Yan, Chaoyi Xia, Chenguang Liu, Caiyun Fu, Yiren Hu, Xi Wang   +9 more
wiley   +1 more source

Antitumor Effect of Curcumin, D6 Turmeric, and Hydrochloride Mitoxantrone on Canine and Human Urothelial Cancer Cells. [PDF]

Animals (Basel)
Silva TOD, Calheiros LGRM, Barbosa F, Morrone FB, Rockenbach L, Lainetti PF, Leis Filho AF, Carvalho M, Fonseca-Alves CE, Laufer Amorim R.   +9 more
europepmc   +1 more source

Aging‐Derived Alterations in Genomic, Immune, and Metabolic Networks: Implications for Cancer Development and Therapy

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Ageing acts as a double‐edged sword in cancer. In the elderly, open chromatin, immunosenescence, and chronic inflammation drive SASP (IL‐6, MMPs), MDSC accumulation and T‐cell suppression, fostering tumor‐promoting microenvironments and limited therapeutic benefit.
Qi Wang, Xue Sun, Xinhao Han, Xingda Zhang, Wenzheng Wang, Hongbin Wang, He Ren, Lina Gu   +7 more
wiley   +1 more source

Survival Trends in Urothelial Cancer Before and After ICIs and Antibody Drug Conjugates.

JAMA Netw Open
Lian Y, Voruganti T, Lu J, Long Q, Mamtani R.   +4 more
europepmc   +1 more source

Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer. [PDF]

Cancer Immunol Res
Galsky MD, Kockx M, Roels J, Van Elzen R, Guan X, Yuen K, Rishipathak D, Anker JF, Gnjatic S, Izadmehr S, Sanjabi S, Johnston RJ, Peterson M, Koeppen H, David JM, Gupta S, Bamias A, Arranz JA, Kikuchi E, De Santis M, Davis ID, Williams P, Bernhard S, Mellman I, Grande E, Banchereau R, Mariathasan S.   +26 more
europepmc   +1 more source

Engineered Elastin‐Like Polypeptides: Intelligent Self‐Assembling Platforms for Biomedical Application

Small Structures, Volume 7, Issue 3, March 2026.
Armed with unique structural and functional properties, elastin‐like polypeptides attract their attentions as programmable materials in biomedical applications, including fusion tags for protein and nucleic acid purification; nanocarriers for protein, chemotherapeutics, and imaging agent delivery; hydrogels for tissue regeneration, 3D model ...
Yang Yuan, Chen Zeng, Zichun Chen, Zhuoga Ciren, Qinran Yu, Chuanbo Wang, Hui Mao, Gang Li, Weizhi Chen, Xiqun Jiang   +9 more
wiley   +1 more source

Challenging Cases in Urothelial Cancer: Case 33. [PDF]

Bladder Cancer
Soloway MS, Abrahams NA, Pinnar N.
europepmc   +1 more source

Effects of Autophagy Inhibition by SAR405, a Selective VPS34 Inhibitor, on Pleural Mesothelioma Cells

Thoracic Cancer, Volume 17, Issue 5, March 2026.
SAR405, a selective VPS34 inhibitor, suppressed autophagic flux and reduced cell viability, colony formation, and invasion in pleural mesothelioma cell lines. SAR405 induced apoptosis only in H2452 cells. Cisplatin weakly induced autophagy, but its combination with SAR405 showed no synergistic cytotoxic effects. ABSTRACT Background Pleural mesothelioma
Yoshiki Kuwabara, Kosuke Sakai, Kota Shiraishi, Itsuka Matsumoto, Shigeru Ishii, Shin Yokosuka, Masatoshi Abe, Tomoyuki Takahashi, Yuichiro Kawano, Hiroaki Nishimura, Maiko Toda‐Sasaki, Yumiko Kobayashi‐Ogawa, Satoshi Kikuchi, Yusuke Hirata, Hiroyuki Kyoyama, Gaku Moriyama, Nobuyuki Koyama, Kazutsugu Uematsu   +17 more
wiley   +1 more source

Risk of metachronous upper tract urothelial carcinoma following non‐muscle‐invasive bladder cancer

BJU International, Volume 137, Issue 3, Page 502-508, March 2026.
Objective To determine the risk and timing of metachronous upper tract urothelial carcinoma (UTUC) after non‐muscle‐invasive bladder cancer (NMIBC). Patients and Methods In this multi‐institutional retrospective cohort study involving academic and community hospitals, clinicopathological data were collected from patients with NMIBC treated between 2005
Keiran J.C. Pace, Jethro C.C. Kwong, Harkanwal Randhawa, Maximiliano Ringa, Zizo Al‐Daqqaq, Yashan Chelliahpillai, Soomin Lee, Kellie Kim, Samuel Haile, Amna Ali, Marian Wettstein, Amy Chan, Nathan Perlis, Jason Lee, Robert Hamilton, Neil Fleshner, Antonio Finelli, Munir Jamal, Frank Papanikolaou, Thomas Short, Andrew Feifer, Girish Kulkarni, Alexandre R. Zlotta   +22 more
wiley   +1 more source